Is Neovacs S.A. (ALNEV.PA) a Buy, Sell, or Hold?
PAR : ALNEV.PA
Neovacs S.A.
$0.742 EUR
-$0.07 (-8.38%)
- Volume
- 2.97K
- Average Volume
- 5.43K
- Market Capitalization
- $35
- P/E Ratio
- -5.71
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $14500.00
- Year Low
- $0.70
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.84
Company Overview
PAR
Hugo Brugiere
Biotechnology
Healthcare
ALNEV.PA
16
FR
EUR
Liquidity Metrics
0.03
0.84
0.84
0.18
0.00
Sales & Valuation
$161.78K
0.00
1.54
0.00
-0.13
Profitability
-$0.13
-$4.9M
-3026.84%
-3415.45%
-27.13%
-22.12%
P/E Metrics
-5.71
-0.07
-0.07
Analyst Price Target & Rating
1/5
0 Analysts
%
Financial Health Scores
-7.06
3/9
-$512.68K
$22.14M
$4.1M
-$21.29M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Vincent Serra | Scientific & Operational Director |
| Charlene Masson | Corporate Communication & Investor Relations |
| Alexandre Courtoux | Administrative & Financial Director |
| Bernard Fanget | Vice President of Pharmaceutical Affairs & Director |
| Hugo Brugiere | Chairman, GM & Chief Executive Officer |
| Daniel Zagury | Founder, Chairman of Scientific Research Committee & Director |
Poll Results
No votes yet today — be the first to share your view!
About Neovacs S.A. (PAR:ALNEV.PA) Stock
Based in Paris, France, Neovacs S.A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases. The company leverages its proprietary Kinoid technology to develop treatments, particularly for chronic autoimmune and inflammatory disorders. Its lead candidate, IFNa Kinoid, an anti-interferon alpha vaccine, is currently undergoing Phase IIb clinical trials for systemic lupus erythematosus and Phase IIa trials for dermatomyositis, with further preclinical investigation for diabetes. Neovacs' pipeline also includes VEGF-Kinoid, which is in preclinical development for both age-related macular degeneration and various solid tumors. Additionally, IL-4/IL-13 Kinoid is in pr ... eclinical stages for allergy treatments. The company has a significant partnership with the Sunnybrook Research Institute, focusing on the preclinical advancement of VEGF Kinoid specifically for colorectal and ovarian cancers.
Frequently Asked Questions
-
What is the current Neovacs S.A. (ALNEV.PA) stock price?
-
Neovacs S.A.(PAR:ALNEV.PA) stock price is $0.742 in the last trading session. During the trading session, ALNEV.PA stock reached the peak price of $14500 while $0.7 was the lowest point it dropped to. The percentage change in ALNEV.PA stock occurred in the recent session was --8.38% while the dollar amount for the price change in ALNEV.PA stock was -$0.07.
-
ALNEV.PA's industry and sector of operation?
-
The PAR listed ALNEV.PA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALNEV.PA?
-
Vincent Serra | Scientific & Operational Director
Charlene Masson | Corporate Communication & Investor Relations
Alexandre Courtoux | Administrative & Financial Director
Bernard Fanget | Vice President of Pharmaceutical Affairs & Director
Hugo Brugiere | Chairman, GM & Chief Executive Officer -
How many employees does ALNEV.PA have?
-
Number of ALNEV.PA employees currently stands at 16. ALNEV.PA operates from 3-5, Impasse Reille, Paris, None 75014, FR.
-
Link for ALNEV.PA official website?
-
Official Website of ALNEV.PA is: https://www.neovacs.com
-
How do I contact ALNEV.PA?
-
ALNEV.PA could be contacted at phone #33 1 53 10 93 00 and can also be accessed through its website. ALNEV.PA operates from 3-5, Impasse Reille, Paris, None 75014, FR.
-
How many shares of ALNEV.PA are traded daily?
-
The average number of ALNEV.PA shares traded daily for last 3 months was 5.43K.
-
What is the market cap of ALNEV.PA currently?
-
The market value of ALNEV.PA currently stands at $35 with its latest stock price at $0.742